Shares in US biotech Biogen (Nasdaq: BIIB) were up by 1.5% following 90 minutes of trading on Wednesday after the company presented its second quarter financial results.
Second quarter total revenues were $3.68 billion, a 2% increase versus the second quarter of 2019 and ahead of analyst expectations of $3.43 billion.
Important to this was Tecfidera (dimethyl fumarate), Biogen’s best-selling treatment, which generated sales of $1.18 billion in the quarter, ahead of Wall Street estimates of $1.11 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze